Carbendazim-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemECarbendazimCat.No.:HY-13582CASNo.:10605-21-7分?式:C?H?N?O?分?量:191.19作?靶點:Fungal;Parasite作?通路:Anti-infection儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:6.8mg/mL(35.57mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM5.2304mL26.1520mL52.3040mL5mM1.0461mL5.2304mL10.4608mL10mM0.5230mL2.6152mL5.2304mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥0.5mg/mL(2.62mM);Clearsolution1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE2.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥0.5mg/mL(2.62mM);ClearsolutionBIOLOGICALACTIVITY?物活性Carbendazim?種有效的，具有?服活性的?服?譜苯并咪唑殺劑(fungicide)，可作為真疾病研究的殺?劑，如孢霉病、鐮?病和核病。Carbendazim?種具有抗腫瘤活性的苯并咪唑(HY-Y1825)衍?物，?于癌癥研究，特別晚期實體腫瘤和淋巴瘤。體外研究Carbendazim(4-60μM;24hours)hasnoeffectsonviabilityofHeLacellsinaCCK-8assay[3].體內(nèi)研究Carbendazim(oralgavage;100and500mg/kg;oncedailyindiet;28days)induceshepaticlipidmetabolismdisorder,itresultsinasignificantincreaseofhepaticlipidaccumulationandtriglyceride(TG)levelsinmice[2].AnimalModel:6-week-oldmaleICRmice[2]Dosage:100and500mg/kgAdministration:Oralgavage;100and500mg/kg;oncedailyindiet;28daysResult:IncreasedtherelativemRNAlevelsofsomekeygenesrelatedtolipogenesisandTGsynthesis.Up-regulatedmRNAlevelsofIL-1bandIL-6intheliverinmice.Increasedtheserumconcentrationsof2proinflammatorycytokinesIL-1bandIL-6at500mg/kg.However,inthefattissues,onlyIL-1bintheCBZ-500-treatedgroupincreasedsignificantlyascomparedwiththecontrolgroup.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?Chemosphere.2022Jan4;133522.?Chemosphere.2021,130769.?Toxics.2021,9(12),349.?ResearchSquarePreprint.2021Aug.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].Carbendazim[2].YuanxiangJin,etal.OralExposureofMicetoCarbendazimInducesHepaticLipidMetabolismDisorderandGutMicrobiotaDysbiosis.ToxicolSci.2015Sep;147(1):116-26[3].BilgeG.Tuna,etal.EnhancedantitumoractivityofcarbendazimonHeLacervicalcancercellsbyaptamermediatedcontrolledrelease.RSCAdvances2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEMcePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplica